



Collaborating to *innovate*

Within our walls and across our industry, collaboration is the way Kyowa Kirin-North America does business. Our history of innovation is built on forming and fostering high-potential collaborations to accelerate delivery of new science and heighten our impact.

Innovation is not just about science. It's also about finding new ways to engage customers, support patients, and empower the health care system to provide optimal care.

Here's how we are partnering, today and in the future:

- Scientific collaborations
- Advocacy and public affairs
- Business development and licensing
- Access, reimbursement, patient support services – Kyowa Kirin Cares

Join us in our *mission*

We're committed to working together to understand clinical needs and opportunities for innovation that result in real advances for patients.

KYOWA KIRIN-NORTH AMERICA

Commercial

135 Route 202/206, Suite 6
Bedminster, NJ 07921
Phone: 908-234-1096

Clinical Development

212 Carnegie Center Drive,
Suite 400
Princeton, NJ 08540
Phone: 609-919-1100

Research & Discovery

9420 Athena Circle
La Jolla, CA 92037
Phone: 858-952-7000



Kyowa Kirin, Inc. - U.S.

CRYSVITA, NOURIANZ, POTELIGEO, POTELLIGENT, and SANCUSO are registered trademarks of Kyowa Hakkō Kirin Co., Ltd.
© 2020 Kyowa Kirin, Inc. All rights reserved. COR-US-KKI-0010. July 2020.

Our medicines


NOURIANZ[®]
(istradefylline) tablets
20 mg | 40 mg


POTELIGEO[®]
(mogamulizumab-kpkc) Injection

Sancuso[®]
(Granisetron Transdermal System)

Additional discoveries from our labs


CRYSVITA[®]
burosumab-twza
Injection for subcutaneous use

LEARN MORE ABOUT THE
IMPACT WE'RE MAKING AT
kyowakirin.com



Novel medicines.
Innovative technologies.
Rewarding work.

Profound *impact.*

Kyowa KIRIN

KYOWA KIRIN

Changing medicine, changing lives



Kyowa Kirin-North America is a specialty pharmaceutical company focused on creating innovative medicines with the latest biotechnology. For more than 30 years, we have pursued scientific discoveries that address unmet clinical needs. We work in an unbroken chain—from research and discovery, through development and commercialization—in order to surmount the challenges of innovating in new frontiers.

Our commitment to advancing breakthroughs has produced a portfolio of specialty medicines with novel mechanisms of action. Since 2018, the company has received approval from the U.S. Food and Drug Administration (FDA) for three first-in-class treatments. These medicines add to Kyowa Kirin's rich history of innovation, delivering treatments for Oncology, Immunology/Allergy, Nephrology and the Central Nervous System.

Grounded by our expertise in antibody engineering, we continue to investigate new molecules with the potential to change medicine and lives.

Values that drive achievement



Commitment to Life



Innovation



Integrity




Teamwork/Wa*

*Wa = The Japanese principle of seeking the harmony of the team over personal interests.


Our pipeline

In North America, we coordinate development work with global colleagues to bring new medicines to patients around the world. Our pipeline includes ongoing trials to evaluate compounds in our four therapeutic areas. Many of our programs target rare diseases where patients lack sufficient treatment options.



North America development pipeline as of July 2020. The safety and efficacy of the investigational compounds or investigational uses of marketed products reflected here have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. Indications that have received regulatory approval are not pictured. *Collaborating with industry partner.

At Kyowa Kirin, everything we do is driven by our goal to have a profound impact on patient lives. Our teams leverage state-of-the-art technologies and R&D capabilities to discover, develop and deliver scientific innovations in four key modalities:



In our research labs, we look for new ways to harness natural mechanisms of the body's immune response to fight disease. For example, our POTELLIGENT® technology boosts antibody-dependent cellular cytotoxicity (ADCC) by reducing the amount of fucose in antibodies to improve the binding activity to immune cells.¹ Discoveries like this provide fertile ground for our pipeline and future partnering opportunities.

To find out more about licensing or business development, email us at BD@kyowakirin.com.

1. Matsushita T. *Korean J Hematol.* 46, 148-150, 2011.